Dr Andrew E Mcquide, MD - Medicare Anesthesiology in Andover, MA

Dr Andrew E Mcquide, MD is a medicare enrolled "Anesthesiology" physician in Andover, Massachusetts. He graduated from medical school in 2001 and has 23 years of diverse experience with area of expertise as Anesthesiology. He is a member of the group practice Massachusetts General Physicians Organization Inc, Pratt Anesthesiology Associates Inc and his current practice location is 11 Durham Dr, Andover, Massachusetts. You can reach out to his office (for appointments etc.) via phone at (978) 289-7880.

Dr Andrew E Mcquide is licensed to practice in New York (license number 235403) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1649231812.

Contact Information

Dr Andrew E Mcquide, MD
11 Durham Dr,
Andover, MA 01810-5500
(978) 289-7880
Not Available



Physician's Profile

Full NameDr Andrew E Mcquide
GenderMale
SpecialityAnesthesiology
Experience23 Years
Location11 Durham Dr, Andover, Massachusetts
Accepts Medicare AssignmentsYes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.
  Medical Education and Training:
  • Dr Andrew E Mcquide graduated from medical school in 2001
  NPI Data:
  • NPI Number: 1649231812
  • Provider Enumeration Date: 03/29/2006
  • Last Update Date: 11/07/2023
  Medicare PECOS Information:
  • PECOS PAC ID: 6709817828
  • Enrollment ID: I20090602000224

Medical Identifiers

Medical identifiers for Dr Andrew E Mcquide such as npi, medicare ID, medicare PIN, medicaid, etc.
IdentifierTypeStateIssuer
1649231812NPI-NPPES
02665887MedicaidNY

Medical Taxonomies and Licenses

TaxonomyTypeLicense (State)Status
207L00000XAnesthesiology 235403 (New York)Primary

Medical Facilities Affiliation

Facility NameLocationFacility Type
North Shore Medical Center -Salem, MAHospital
Tufts Medical CenterBoston, MAHospital

Group Practice Association

Group Practice NameGroup PECOS PAC IDNo. of Members
Massachusetts General Physicians Organization Inc24663658203085
Pratt Anesthesiology Associates Inc0547151151137

News Archive

Developing high field solid-state NMR for the characterization of complex targets

Solid-state NMR spectroscopy is a technique used by scientists to provide valuable information in the analysis of solid materials. It provides unique and specific insights into the structure, dynamics, and reactivity of all kinds of materials.

Today Zealous intends to sell its subsidiary to pay off legacy debt

Today Zealous, Inc. announced that it is considering selling its stake in Zealous Interactive in order to monetize the valued asset and reduce its legacy debt.

Drug-eluting endotracheal tubes for preventing airway complications

In a proof-of-concept study, researchers at Children's Hospital of Philadelphia have created a coating that can be applied to endotracheal tubes and release antimicrobial peptides that target infectious bacteria with specificity.

New alliance for discovery of WNT pathway inhibitors to be used in cancer therapy

Cancer Research Technology (CRT), Merck Serono, a division of Merck KGaA, Darmstadt, Germany, Cancer Research UK, Cardiff University and The Institute of Cancer Research (ICR) are set to begin a major new research collaboration for the first time. This will provide substantial investment in research on the WNT signalling pathway in the hope of finding new drug targets.

Researchers find new therapy to prevent drug resistance for melanoma patients

Mount Sinai researchers have discovered a previously unknown reason for drug resistance in a common subtype of melanoma, one of the deadliest forms of cancer, and in turn, have found a new therapy that could prevent or reverse drug resistance for melanoma patients with a particular gene mutation, according to a study published in Nature Communications in August.

Read more Medical News

› Verified 4 days ago

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Dr Andrew E Mcquide allows following entities to bill medicare on his behalf.
Entity NameMassachusetts General Physicians Organization Inc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1801874573
PECOS PAC ID: 2466365820
Enrollment ID: O20031111000434

News Archive

Developing high field solid-state NMR for the characterization of complex targets

Solid-state NMR spectroscopy is a technique used by scientists to provide valuable information in the analysis of solid materials. It provides unique and specific insights into the structure, dynamics, and reactivity of all kinds of materials.

Today Zealous intends to sell its subsidiary to pay off legacy debt

Today Zealous, Inc. announced that it is considering selling its stake in Zealous Interactive in order to monetize the valued asset and reduce its legacy debt.

Drug-eluting endotracheal tubes for preventing airway complications

In a proof-of-concept study, researchers at Children's Hospital of Philadelphia have created a coating that can be applied to endotracheal tubes and release antimicrobial peptides that target infectious bacteria with specificity.

New alliance for discovery of WNT pathway inhibitors to be used in cancer therapy

Cancer Research Technology (CRT), Merck Serono, a division of Merck KGaA, Darmstadt, Germany, Cancer Research UK, Cardiff University and The Institute of Cancer Research (ICR) are set to begin a major new research collaboration for the first time. This will provide substantial investment in research on the WNT signalling pathway in the hope of finding new drug targets.

Researchers find new therapy to prevent drug resistance for melanoma patients

Mount Sinai researchers have discovered a previously unknown reason for drug resistance in a common subtype of melanoma, one of the deadliest forms of cancer, and in turn, have found a new therapy that could prevent or reverse drug resistance for melanoma patients with a particular gene mutation, according to a study published in Nature Communications in August.

Read more Medical News

› Verified 4 days ago

Entity NamePratt Anesthesiology Associates Inc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1326085390
PECOS PAC ID: 0547151151
Enrollment ID: O20040323001056

News Archive

Developing high field solid-state NMR for the characterization of complex targets

Solid-state NMR spectroscopy is a technique used by scientists to provide valuable information in the analysis of solid materials. It provides unique and specific insights into the structure, dynamics, and reactivity of all kinds of materials.

Today Zealous intends to sell its subsidiary to pay off legacy debt

Today Zealous, Inc. announced that it is considering selling its stake in Zealous Interactive in order to monetize the valued asset and reduce its legacy debt.

Drug-eluting endotracheal tubes for preventing airway complications

In a proof-of-concept study, researchers at Children's Hospital of Philadelphia have created a coating that can be applied to endotracheal tubes and release antimicrobial peptides that target infectious bacteria with specificity.

New alliance for discovery of WNT pathway inhibitors to be used in cancer therapy

Cancer Research Technology (CRT), Merck Serono, a division of Merck KGaA, Darmstadt, Germany, Cancer Research UK, Cardiff University and The Institute of Cancer Research (ICR) are set to begin a major new research collaboration for the first time. This will provide substantial investment in research on the WNT signalling pathway in the hope of finding new drug targets.

Researchers find new therapy to prevent drug resistance for melanoma patients

Mount Sinai researchers have discovered a previously unknown reason for drug resistance in a common subtype of melanoma, one of the deadliest forms of cancer, and in turn, have found a new therapy that could prevent or reverse drug resistance for melanoma patients with a particular gene mutation, according to a study published in Nature Communications in August.

Read more Medical News

› Verified 4 days ago

Entity NameNarragansett Bay Anesthesia Llc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1861445728
PECOS PAC ID: 5991774929
Enrollment ID: O20050714000216

News Archive

Developing high field solid-state NMR for the characterization of complex targets

Solid-state NMR spectroscopy is a technique used by scientists to provide valuable information in the analysis of solid materials. It provides unique and specific insights into the structure, dynamics, and reactivity of all kinds of materials.

Today Zealous intends to sell its subsidiary to pay off legacy debt

Today Zealous, Inc. announced that it is considering selling its stake in Zealous Interactive in order to monetize the valued asset and reduce its legacy debt.

Drug-eluting endotracheal tubes for preventing airway complications

In a proof-of-concept study, researchers at Children's Hospital of Philadelphia have created a coating that can be applied to endotracheal tubes and release antimicrobial peptides that target infectious bacteria with specificity.

New alliance for discovery of WNT pathway inhibitors to be used in cancer therapy

Cancer Research Technology (CRT), Merck Serono, a division of Merck KGaA, Darmstadt, Germany, Cancer Research UK, Cardiff University and The Institute of Cancer Research (ICR) are set to begin a major new research collaboration for the first time. This will provide substantial investment in research on the WNT signalling pathway in the hope of finding new drug targets.

Researchers find new therapy to prevent drug resistance for melanoma patients

Mount Sinai researchers have discovered a previously unknown reason for drug resistance in a common subtype of melanoma, one of the deadliest forms of cancer, and in turn, have found a new therapy that could prevent or reverse drug resistance for melanoma patients with a particular gene mutation, according to a study published in Nature Communications in August.

Read more Medical News

› Verified 4 days ago

Entity NameThe General Hospital Corporation
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1023049236
PECOS PAC ID: 6507803806
Enrollment ID: O20080313000351

News Archive

Developing high field solid-state NMR for the characterization of complex targets

Solid-state NMR spectroscopy is a technique used by scientists to provide valuable information in the analysis of solid materials. It provides unique and specific insights into the structure, dynamics, and reactivity of all kinds of materials.

Today Zealous intends to sell its subsidiary to pay off legacy debt

Today Zealous, Inc. announced that it is considering selling its stake in Zealous Interactive in order to monetize the valued asset and reduce its legacy debt.

Drug-eluting endotracheal tubes for preventing airway complications

In a proof-of-concept study, researchers at Children's Hospital of Philadelphia have created a coating that can be applied to endotracheal tubes and release antimicrobial peptides that target infectious bacteria with specificity.

New alliance for discovery of WNT pathway inhibitors to be used in cancer therapy

Cancer Research Technology (CRT), Merck Serono, a division of Merck KGaA, Darmstadt, Germany, Cancer Research UK, Cardiff University and The Institute of Cancer Research (ICR) are set to begin a major new research collaboration for the first time. This will provide substantial investment in research on the WNT signalling pathway in the hope of finding new drug targets.

Researchers find new therapy to prevent drug resistance for melanoma patients

Mount Sinai researchers have discovered a previously unknown reason for drug resistance in a common subtype of melanoma, one of the deadliest forms of cancer, and in turn, have found a new therapy that could prevent or reverse drug resistance for melanoma patients with a particular gene mutation, according to a study published in Nature Communications in August.

Read more Medical News

› Verified 4 days ago

Entity NameSteward Medical Group Inc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1629398219
PECOS PAC ID: 2860688728
Enrollment ID: O20101119000332

News Archive

Developing high field solid-state NMR for the characterization of complex targets

Solid-state NMR spectroscopy is a technique used by scientists to provide valuable information in the analysis of solid materials. It provides unique and specific insights into the structure, dynamics, and reactivity of all kinds of materials.

Today Zealous intends to sell its subsidiary to pay off legacy debt

Today Zealous, Inc. announced that it is considering selling its stake in Zealous Interactive in order to monetize the valued asset and reduce its legacy debt.

Drug-eluting endotracheal tubes for preventing airway complications

In a proof-of-concept study, researchers at Children's Hospital of Philadelphia have created a coating that can be applied to endotracheal tubes and release antimicrobial peptides that target infectious bacteria with specificity.

New alliance for discovery of WNT pathway inhibitors to be used in cancer therapy

Cancer Research Technology (CRT), Merck Serono, a division of Merck KGaA, Darmstadt, Germany, Cancer Research UK, Cardiff University and The Institute of Cancer Research (ICR) are set to begin a major new research collaboration for the first time. This will provide substantial investment in research on the WNT signalling pathway in the hope of finding new drug targets.

Researchers find new therapy to prevent drug resistance for melanoma patients

Mount Sinai researchers have discovered a previously unknown reason for drug resistance in a common subtype of melanoma, one of the deadliest forms of cancer, and in turn, have found a new therapy that could prevent or reverse drug resistance for melanoma patients with a particular gene mutation, according to a study published in Nature Communications in August.

Read more Medical News

› Verified 4 days ago

Entity NameSteward Medical Group Inc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1043711914
PECOS PAC ID: 2860688728
Enrollment ID: O20180329001196

News Archive

Developing high field solid-state NMR for the characterization of complex targets

Solid-state NMR spectroscopy is a technique used by scientists to provide valuable information in the analysis of solid materials. It provides unique and specific insights into the structure, dynamics, and reactivity of all kinds of materials.

Today Zealous intends to sell its subsidiary to pay off legacy debt

Today Zealous, Inc. announced that it is considering selling its stake in Zealous Interactive in order to monetize the valued asset and reduce its legacy debt.

Drug-eluting endotracheal tubes for preventing airway complications

In a proof-of-concept study, researchers at Children's Hospital of Philadelphia have created a coating that can be applied to endotracheal tubes and release antimicrobial peptides that target infectious bacteria with specificity.

New alliance for discovery of WNT pathway inhibitors to be used in cancer therapy

Cancer Research Technology (CRT), Merck Serono, a division of Merck KGaA, Darmstadt, Germany, Cancer Research UK, Cardiff University and The Institute of Cancer Research (ICR) are set to begin a major new research collaboration for the first time. This will provide substantial investment in research on the WNT signalling pathway in the hope of finding new drug targets.

Researchers find new therapy to prevent drug resistance for melanoma patients

Mount Sinai researchers have discovered a previously unknown reason for drug resistance in a common subtype of melanoma, one of the deadliest forms of cancer, and in turn, have found a new therapy that could prevent or reverse drug resistance for melanoma patients with a particular gene mutation, according to a study published in Nature Communications in August.

Read more Medical News

› Verified 4 days ago

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Andrew E Mcquide is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing AddressPractice Location Address
Dr Andrew E Mcquide, MD
Po Box 725,
Cooperstown, NY 13326-0725

Ph: (607) 547-3909
Dr Andrew E Mcquide, MD
11 Durham Dr,
Andover, MA 01810-5500

Ph: (978) 289-7880

News Archive

Developing high field solid-state NMR for the characterization of complex targets

Solid-state NMR spectroscopy is a technique used by scientists to provide valuable information in the analysis of solid materials. It provides unique and specific insights into the structure, dynamics, and reactivity of all kinds of materials.

Today Zealous intends to sell its subsidiary to pay off legacy debt

Today Zealous, Inc. announced that it is considering selling its stake in Zealous Interactive in order to monetize the valued asset and reduce its legacy debt.

Drug-eluting endotracheal tubes for preventing airway complications

In a proof-of-concept study, researchers at Children's Hospital of Philadelphia have created a coating that can be applied to endotracheal tubes and release antimicrobial peptides that target infectious bacteria with specificity.

New alliance for discovery of WNT pathway inhibitors to be used in cancer therapy

Cancer Research Technology (CRT), Merck Serono, a division of Merck KGaA, Darmstadt, Germany, Cancer Research UK, Cardiff University and The Institute of Cancer Research (ICR) are set to begin a major new research collaboration for the first time. This will provide substantial investment in research on the WNT signalling pathway in the hope of finding new drug targets.

Researchers find new therapy to prevent drug resistance for melanoma patients

Mount Sinai researchers have discovered a previously unknown reason for drug resistance in a common subtype of melanoma, one of the deadliest forms of cancer, and in turn, have found a new therapy that could prevent or reverse drug resistance for melanoma patients with a particular gene mutation, according to a study published in Nature Communications in August.

Read more News

› Verified 4 days ago


Anesthesiology Doctors in Andover, MA

Rostislava Kanyuk-stoupnitska, MD
Anesthesiology
Medicare: Accepting Medicare Assignments
Practice Location: 138 Haverhill Street, Andover, MA 01810
Phone: 978-296-2302    Fax: 978-296-2304
Dr. Ki-il Kim, M.D
Anesthesiology
Medicare: Not Enrolled in Medicare
Practice Location: 5 Worthen Pl, Andover, MA 01810
Phone: 978-475-0731    Fax: 978-475-0731
Dr. Eduardo O Dagostino, MD
Anesthesiology
Medicare: Medicare Enrolled
Practice Location: 349 N Main St, Andover, MA 01810
Phone: 978-475-0959    Fax: 978-475-1769

Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.